CAJ | 학술논문

乐伐替尼（Lenvatinib）是由日本卫材公司研制的口服多靶点酪氨酸激酶抑制剂（TKI）。2015年2月，美国FDA批准其用于晚期放射性-碘难治性分化型甲状腺癌的治疗，或将成为不可切除性甲状腺癌临床治疗的新标准。业界对乐伐替尼非常看好，其在肾细胞癌等其他适应证方面的研究也值得期待。笔者就乐伐替尼的基本性质、作用机制、药动学、药效学、临床试验及应用等研发动态作一概述，以期能为医院临床用药起到指导作用。
악벌체니（Lenvatinib）시유일본위재공사연제적구복다파점락안산격매억제제（TKI）。2015년2월，미국FDA비준기용우만기방사성-전난치성분화형갑상선암적치료，혹장성위불가절제성갑상선암림상치료적신표준。업계대악벌체니비상간호，기재신세포암등기타괄응증방면적연구야치득기대。필자취악벌체니적기본성질、작용궤제、약동학、약효학、림상시험급응용등연발동태작일개술，이기능위의원림상용약기도지도작용。
Lenvatinib is an oral multiple receptor tyrosine kinase inhibitor (TKI) developed by Eisai. In February 2005, Lenvatinib has been approved for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC), which provides an option to alleviate the seriously unmet medical needs for thyroid cancer. People generally believe that the future of lenvatinib is promising, and the studies of lenvatinib in renal cell carcinoma and other indications are also really to be expected. In this paper, the development process, properties, mechanism, pharmacokinetics, pharmacodynamics, clinical trials and applications of lenvatinib are summarized, in order to provide reference for clinical treatment.